CERNER CORP /MO/ Form 10-Q July 26, 2013 <u>Table of Contents</u>	
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (X) QUARTERLY REPORT PURSUANT TO SECTION 13 O	R 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 For the quarterly period ended: June 29, 2013 OR	K 15(d) OF THE SECONTIES EXCITATOL ACT
() TRANSITION REPORT PURSUANT TO SECTION 13 OR OF 1934	15(d) OF THE SECURITIES EXCHANGE ACT
For the transition period from to Commission File Number: 0-15386	
CERNER CORPORATION	
(Exact name of registrant as specified in its charter)	42 110(044
Delaware (State or other jurisdiction of	43-1196944 (I.R.S. Employer Identification
incorporation or organization)	Number)
2800 Rockcreek Parkway	
North Kansas City, MO	64117
(Address of principal executive offices) (816) 201-1024	(Zip Code)
(Registrant's telephone number, including area code)	
Indicate by check mark whether the registrant (1) has filed all reports Securities Exchange Act of 1934 during the preceding 12 months required to file such reports), and (2) has been subject to such filing Yes $[X]$ No $[$	(or for such shorter period that the registrant was
Indicate by check mark whether the registrant has submitted electrany, every Interactive Data File required to be submitted and poster ($\$232.405$ of this chapter) during the preceding 12 months (or for to submit and post such files). Yes [X] No []	ed pursuant to Rule 405 of Regulation S-T
Indicate by check mark whether the registrant is a large accelerate or a smaller reporting company. See the definitions of "large accelerate company" in Rule 12b-2 of the Exchange Act.	lerated filer," "accelerated filer," and "smaller reporting
Large accelerated filer [X] Accelerated filer [] Non-accelerated filer [] Non-accelerated filer [] Non-accelerated filer [] Non-accelerated filer [] No [X]	ated filer [] Smaller reporting company [] (as defined in Rule 12b-2 of the Exchange Act).
Indicate the number of shares outstanding of the issuer's classes of Class Common Stock, \$0.01 par value per share	f common stock, as of the latest practicable date. Outstanding at July 19, 2013 343,108,150 shares

CERNER CORPORATION

TABLE OF CONTENTS

- Part I. Financial Information:
- Item 1. Financial Statements:

	Condensed Consolidated Balance Sheets as of June 29, 2013 (unaudited) and December 29, 2012	<u>1</u>
	Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 29, 2013 and June 30, 2012 (unaudited)	<u>2</u>
	Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 29, 2013 and June 30, 2012 (unaudited)	<u>3</u>
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 29, 2013 and June 30, 2012 (unaudited)	<u>4</u>
	Notes to Condensed Consolidated Financial Statements (unaudited)	<u>5</u>
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>16</u>
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	<u>27</u>
Item 4.	Controls and Procedures	<u>27</u>
Part II.	Other Information:	
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	<u>28</u>
Item 6.	Exhibits	<u>29</u>
Signature	28	

Part I. Financial Information

Item 1. Financial Statements

CERNER CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS As of June 29, 2013 (unaudited) and December 29, 2012 (In thousands, except share data)	2013	2012
Assets		
Current assets:		
Cash and cash equivalents	\$270,764	\$317,120
Short-term investments	698,754	719,665
Receivables, net	527,896	577,848
Inventory	23,835	23,681
Prepaid expenses and other	152,743	113,572
Deferred income taxes, net	39,304	38,620
Total current assets	1,713,296	1,790,506
Property and equipment, net	674,626	569,708
Software development costs, net	299,837	267,307
Goodwill	306,951	247,616
Intangible assets, net	144,141	132,045
Long-term investments	513,762	509,467
Other assets	191,328	187,819
Total assets	\$3,843,941	\$3,704,468
	\$5,045,941	\$J,704,400
Liabilities and Shareholders' Equity		
Current liabilities:		
Accounts payable	\$169,735	\$141,212
Current installments of long-term debt and capital lease obligations	48,928	59,582
Deferred revenue	179,182	189,652
Accrued payroll and tax withholdings	122,600	125,253
Other accrued expenses	84,995	64,413
Total current liabilities	605,440	580,112
Long-term debt and capital lease obligations	132,971	136,557
Deferred income taxes and other liabilities	132,971 145,984	130,337
Deferred revenue	8,539	143,212
	-	
Total liabilities	892,934	870,818
Shareholders' Equity:		
Common stock, \$.01 par value, 500,000,000 shares authorized, 343,030,734 shares issued	3,430	3,442
at June 29, 2013 and 344,178,702 shares issued at December 29, 2012	5,450	5,442
Additional paid-in capital	754,256	840,769
Retained earnings	2,217,641	1,994,694
Accumulated other comprehensive loss, net	(24,320)	(5,255)

Total shareholders' equity	2,951,007	2,833,650
Total liabilities and shareholders' equity	\$3,843,941	\$3,704,468
See notes to condensed consolidated financial statements (unaudited).		

CERNER CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the three and six months ended June 29, 2013 and June 30, 2012 (unaudited)

	Three Months Ended		Six Months Ended	
(In thousands, except per share data)	2013	2012	2013	2012
Revenues:				
System sales	\$200,503	\$195,295	\$399,405	\$421,115
Support, maintenance and services	486,647	426,046	953,203	829,950
Reimbursed travel	20,411	16,017	34,982	27,505
Total revenues	707,561	637,358	1,387,590	1,278,570
Costs and expenses:				
Cost of system sales	71,708	100,570	153,191	217,525
Cost of support, maintenance and services	33,681	30,913	64,856	60,478
Cost of reimbursed travel	20,411	16,017	34,982	27,505
Sales and client service	281,192	241,875	548,548	486,949
Software development (Includes amortization of \$23,294 and \$45,310		,	,	,
for the three and six months ended June 29, 2013; and \$20,084 and	82,282	73,507	163,345	144,652
\$39,473 for the three and six months ended June 30, 2012)			,	,
General and administrative	51,831	38,393	99,643	77,939
	,	,	,	,
Total costs and expenses	541,105	501,275	1,064,565	1,015,048
-				
Operating earnings	166,456	136,083	323,025	263,522
Other income, net	2,733	2,814	5,777	5,438
Earnings before income taxes	169,189	138,897	328,802	268,960
Income taxes	(56,282)	(41,068)	(105,855)	(82,423)
Net earnings	\$112,907	\$97,829	\$222,947	\$186,537
	¢0.22	¢ 0 20	¢0.65	¢0.55
Basic earnings per share	\$0.33 \$0.22	\$0.29	\$0.65	\$0.55 \$0.52
Diluted earnings per share	\$0.32	\$0.28	\$0.63	\$0.53
Basic weighted average shares outstanding	343,800	341,426	343,976	340,671
Diluted weighted average shares outstanding	352,485	351,268	352,714	350,666
See notes to condensed consolidated financial statements (unaudited).				

CERNER CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME For the three and six months ended June 29, 2013 and June 30, 2012 (unaudited)

(In thousands)	Three Mon 2013	ths Ended 2012	Six Month 2013	s Ended 2012
Net earnings	\$112,907	\$97,829	\$222,947	\$186,537
Foreign currency translation adjustment and other (net of taxes (benefit) of \$(2,464) and \$(618) for the three and six months ended June 29, 2013; and \$96 and \$(635) for the three and six months ended June 30, 2012)	(8,997)	(8,961)	(18,205)	(993)
Unrealized holding gain (loss) on available-for-sale investments (net of taxes (benefit) of \$(658) and \$(543) for the three and six months ended June 29, 2013; and \$17 and \$17 for the three and six months ended June 30, 2012)	(1,036)	28	(860)	28
Comprehensive income	\$102,874	\$88,896	\$203,882	\$185,572
See notes to condensed consolidated financial statements (unaudited).				

CERNER CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS For the six months ended June 29, 2013 and June 30, 2012 (unaudited)

(In thousands)	Six Month 2013	s Ended 2012
CASH FLOWS FROM OPERATING ACTIVITIES: Net earnings	\$222,947	\$186,537
Adjustments to reconcile net earnings to net cash provided by operating activities: Depreciation and amortization Share-based compensation expense	122,232 21,123	106,215 16,583
Provision for deferred income taxes Changes in assets and liabilities (net of businesses acquired):	1,470	(10,480)
Receivables, net Inventory	38,985 450	31,282 878
Prepaid expenses and other Accounts payable	5,471	(13,898) 15,059
Accrued income taxes Deferred revenue Other accrued liabilities	11,025 (12,166) 6,620	(29,459) 8,140 34,690
Net cash provided by operating activities	390,155	345,547
CASH FLOWS FROM INVESTING ACTIVITIES:	,	,
Capital purchases		(78,164)
Capitalized software development costs Purchases of investments	(77,907) (537,328)	(46,847) (655,310)
Sales and maturities of investments	533,606	
Purchase of other intangibles	(35,772)	
Acquisition of businesses, net of cash acquired	(67,802)	—
Net cash used in investing activities	(320,190)	(339,046)
CASH FLOWS FROM FINANCING ACTIVITIES:		<i></i>
Repayment of long-term debt and capital lease obligations		(1,438)
Proceeds from excess tax benefits from share-based compensation Proceeds from exercise of options	21,675 16,975	30,101 25,044
Treasury stock purchases	(141,791)	
Contingent consideration payments for acquisition of businesses	(800)	
Other	475	_
Net cash provided by (used in) financing activities	(113,216)	53,707
Effect of exchange rate changes on cash and cash equivalents	(3,105)	(566)
Net increase (decrease) in cash and cash equivalents		59,642
Cash and cash equivalents at beginning of period	317,120	243,146

Cash and cash equivalents at end of period	\$270,764	\$302,788
Summary of acquisition transactions:		
Fair value of net tangible assets acquired	\$1,496	\$—
Fair value of intangible assets acquired	25,489	
Fair value of goodwill	60,452	_
Less: Fair value of contingent liability payable	(18,982)	
Cash paid for acquisitions	68,455	
Cash acquired	(653)	—
Net cash used See notes to condensed consolidated financial statements (unaudited).	\$67,802	\$—

CERNER CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(1) Interim Statement Presentation

The condensed consolidated financial statements included herein have been prepared by Cerner Corporation (we or the Company) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in our latest annual report on Form 10-K.

In management's opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the financial position and the results of operations and cash flows for the periods presented. Our interim results as presented in this Form 10-Q are not necessarily indicative of the operating results for the entire year.

The condensed consolidated financial statements were prepared using GAAP. These principles require us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results could differ from those estimates.

Our second fiscal quarter ends on the Saturday closest to June 30. The 2013 and 2012 second quarters ended on June 29, 2013 and June 30, 2012, respectively. All references to years in these notes to condensed consolidated financial statements represent the respective three or six months ended on such dates, unless otherwise noted.

Stock Split

On May 24, 2013, the Board of Directors of the Company approved a two-for-one split of our common stock in the form of a one hundred percent (100%) stock dividend, which was distributed on or about June 28, 2013 to shareholders of record as of June 17, 2013. In connection with the stock split, 1.5 million treasury shares (pre-split), which represents the amount held in treasury on June 28, 2013, were utilized to settle a portion of the distribution. All share and per share data have been retroactively adjusted for all periods presented to reflect the stock split including the use of treasury shares, as if the stock split had occurred at the beginning of the earliest period presented.

Under the terms of our outstanding equity awards, the stock split increased the number of shares of our common stock issuable upon exercise or vesting of such awards in proportion to the stock split ratio and caused a proportionate decrease in the exercise price of such awards to the extent they were stock options.

Recently Adopted Accounting Pronouncements

Comprehensive Income. In the first quarter of 2013, we adopted Financial Accounting Standards Board Accounting Standards Update (ASU) No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (AOCI). ASU 2013-02 requires an entity to disclose, either in a single note or parenthetically on the face of the financial statements, the effect of significant amounts reclassified from each component of AOCI into net income and the income statement line items affected by the reclassification. If a component is not required to be reclassified to net income in its entirety, an entity would instead cross reference to the related footnote for additional information. The adoption of this standard did not impact disclosures in these condensed consolidated financial statements, as AOCI reclassification amounts are not material to the Company.

(2) Business Acquisitions

PureWellness

On March 4, 2013, we purchased the net assets of Kaufman & Keen, LLC (doing business as PureWellness). PureWellness is a health and wellness company that develops solutions for the administration and management of wellness programs, and to enable plan member engagement strategies. Our acquisition of PureWellness will further expand what we believe to be a robust offering of solutions to manage and improve the health of populations.

Consideration for the acquisition of PureWellness is expected to total \$69.1 million consisting of up-front cash plus contingent consideration, which is payable if we achieve certain revenue milestones from PureWellness solutions and services during the period commencing on August 1, 2013 and ending April 30, 2015. We valued the contingent consideration at \$19.0 million based on a probability-weighted assessment of potential contingent consideration payment scenarios.

The acquisition of PureWellness is being treated as a purchase in accordance with ASC 805, Business Combinations, which requires allocation of the purchase price to the estimated fair values of assets and liabilities acquired in the transaction. The allocation of purchase price is based on management's judgment after evaluating several factors, including a preliminary valuation assessment. The allocation of purchase price is subject to changes as an appraisal of intangible assets is finalized and additional information becomes available; however, we do not expect material changes. The following is a summary of the preliminary allocation of purchase price:

(In thousands)	Allocation Amount
Tangible assets and liabilities Current assets Property and equipment Current liabilities Total net tangible assets	\$1,427 240 (1,315) 352
Intangible assets Customer relationships Existing technologies Total intangible assets	10,464 9,805 20,269
Goodwill Total purchase price	48,496 \$69,117

The fair values of the acquired intangible assets were estimated by applying the income approach. Such estimations required the use of inputs that were unobservable in the market place (Level 3), including a discount rate that we estimated would be used by a market participant in valuing these assets, projections of revenues and cash flows, and client attrition rates, among others. See Note (3) for further information about the fair value level hierarchy.

The goodwill of \$48.5 million arising from the acquisition consists largely of the synergies and economies of scale, including the value of the assembled workforce, expected from combining the operations of Cerner and PureWellness. All of the goodwill was allocated to our Domestic operating segment and is expected to be deductible for tax purposes. Identifiable intangible assets are being amortized over a weighted-average period of seven years. The

operating results of PureWellness were combined with our operating results subsequent to the purchase date of March 4, 2013. Pro-forma results of operations, assuming this acquisition was made at the beginning of the earliest period presented, have not been presented because the effect of this acquisition was not material to our results.

Labotix

On March 18, 2013, we purchased 100% of the outstanding stock of Labotix Corporation (together with its wholly owned subsidiary Labotix Automation, Inc., Labotix). Labotix is a developer of laboratory automation solutions for clinical laboratories.

We believe the combination of Cerner Millennium, Cerner Copath, and Labotix allows us to offer a comprehensive set of capabilities to support high volume laboratory testing.

Consideration for the acquisition of Labotix was \$18.0 million, which was paid in cash. The preliminary allocation of purchase price to the estimated fair value of the identified tangible and intangible assets acquired and liabilities assumed resulted in goodwill of \$11.7 million and \$5.2 million in intangible assets related to the value of existing technologies. The allocation of purchase price is subject to changes as a working capital adjustment is finalized and additional information becomes available; however, we do not expect material changes. The goodwill was allocated to our Domestic operating segment and is not expected to be deductible for tax purposes. Identifiable intangible assets are being amortized over a period of five years.

The operating results of Labotix were combined with our operating results subsequent to the purchase date of March 18, 2013. Pro-forma results of operations have not been presented because the effect of this acquisition was not material to our results.

(3) Fair Value Measurements

We determine fair value measurements used in our consolidated financial statements based upon the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1 – Valuations based on quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.

Level 2 – Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.

Level 3 – Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table details our financial assets measured and recorded at fair value on a recurring basis at June 29, 2013:

(In thousands)

(111 0110 00 001000)		Fair Valu	e Measuren	nents Using
Description	Balance Sheet Classification	Level 1	Level 2	Level 3
Money market funds	Cash equivalents	\$28,921	\$—	\$—
Time deposits	Cash equivalents		10,499	
Government and corporate bonds	Cash equivalents	_	1,065	_
Time deposits	Short-term investments		50,987	
Commercial paper	Short-term investments		81,512	
Government and corporate bonds	Short-term investments		566,255	_
Time deposits	Long-term investments	—	3,993	

Government and corporate bonds Long-term investments

502,607 —

The following table details our financial assets measured and recorded at fair value on a recurring basis at December 29, 2012:

(In thousands)

	Fair			Value Measurements			
		Using					
Description	Balance Sheet Classification	Level 1	Level 2	Level 3			
Money market funds	Cash equivalents	\$68,267	\$—	\$—			
Time deposits	Cash equivalents	_	24,068				
Time deposits	Short-term investments	_	90,550				
Commercial paper	Short-term investments		86,458				
Government and corporate bonds	Short-term investments	—	542,657				
Time deposits	Long-term investments		6,197				
Government and corporate bonds	Long-term investments		496,770				

We estimate the fair value of our long-term, fixed rate debt using a Level 3 discounted cash flow analysis based on current borrowing rates for debt with similar maturities. The fair value of our long-term debt, including current maturities, at June 29, 2013 and December 29, 2012 was approximately \$45.1 million and \$59.0 million, respectively. The carrying amount of such fixed-rate debt at June 29, 2013 and December 29, 2012 was \$42.4 million and \$54.8 million, respectively.

(4) Investments

Available-for-sale investments at June 29, 2013 were as follows:

(In thousands)	Adjusted Cost	Gross Unrealized Gains	Gross Unrealized Losses	t	Fair Value
Cash equivalents:					
Money market funds	\$28,921	\$—	\$ <i>—</i>		\$28,921
Time deposits	10,499		_		10,499
Government and corporate bonds	1,065				1,065
Total cash equivalents	40,485				40,485
Short-term investments:					
Time deposits	50,985	3	(1)	50,987
Commercial paper	81,500	24	(12)	81,512
Government and corporate bonds	566,013	362	(120)	566,255
Total short-term investments	698,498	389	(133)	698,754
Long-term investments:					
Time deposits	3,985	10	(2)	3,993
Government and corporate bonds	503,948	56	(1,397)	502,607
Total long-term investments	507,933	66	(1,399)	506,600
Total available-for-sale investments	\$1,246,916	\$ 455	\$(1,532)	\$1,245,839

Available-for-sale investments at December 29, 2012 were as follows:

(In thousands)	Adjusted Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Cash equivalents:				
Money market funds	\$68,267	\$ —	\$ <i>—</i>	\$68,267
Time deposits	24,068			24,068
Total cash equivalents	92,335			92,335
Short-term investments:				
Time deposits	90,535	17	(2)	90,550
Commercial paper	86,500	15	(57)	86,458
Government and corporate bonds	542,236	497	(76)	542,657
Total short-term investments	719,271	529	(135)	719,665
Long-term investments:				
Time deposits	6,190	10	(3)	6,197
Government and corporate bonds	496,845	324	(399)	496,770
Total long-term investments	503,035	334	(402)	502,967
Total available-for-sale investments	\$1,314,641	\$ 863	\$ (537)	\$1,314,967

Investments reported under the cost method of accounting as of June 29, 2013 and December 29, 2012 were \$7.2 million and \$6.5 million, respectively.

We sold available-for-sale investments for proceeds of \$40.8 million and \$8.5 million during the six months ended June 29, 2013 and June 30, 2012, respectively, resulting in insignificant gains in each period.

(5) Receivables

A summary of net receivables is as follows:

(In thousands)	June 29, 2013	December 29, 2012
Gross accounts receivable Less: Allowance for doubtful accounts	\$525,208 30,387	\$ 581,386 33,230
Accounts receivable, net of allowance	494,821	548,156
Current portion of lease receivables	33,075	29,692
Total receivables, net	\$527,896	\$ 577,848

During the second quarter of 2008, Fujitsu Services Limited's (Fujitsu) contract as the prime contractor in the National Health Service (NHS) initiative to automate clinical processes and digitize medical records in the Southern region of England was terminated by the NHS. This had the effect of automatically terminating our subcontract for the project. We are in dispute with Fujitsu regarding Fujitsu's obligation to pay the amounts comprised of accounts receivable and contracts receivable related to that subcontract, and we are working with Fujitsu to resolve these issues

based on processes provided for in the contract. Part of that process requires resolution of disputes between Fujitsu and the NHS regarding the contract termination. As of June 29, 2013, it remains unlikely that our matter with Fujitsu will be resolved in the next 12 months. Therefore, these receivables have been classified as long-term and represent less than the majority of other long-term assets at June 29, 2013 and December 29, 2012. While the ultimate collectability of the receivables pursuant to this process is uncertain, we believe that we have valid and equitable grounds for recovery of such amounts and that collection of recorded amounts is probable.

During the first six months of 2013 and 2012, we received total client cash collections of \$1.5 billion and \$1.4 billion, respectively, of which \$30.0 million and \$32.5 million were received from third party arrangements with non-recourse payment assignments.

(6) Income Taxes

We determine the tax provision for interim periods using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter we update our estimate of the annual effective tax rate, and if our estimated tax rate changes, we make a cumulative adjustment.

Our effective tax rate was 32.2% and 30.6% for the first six months of 2013 and 2012, respectively. This increase was primarily due to a decrease in net favorable discrete items recorded in 2013 relative to 2012, partially offset by reinstatement of the research and development credit in 2013.

In January 2013, the American Taxpayer Relief Act of 2012 (Act) became law. The Act reinstates the research and development tax credit retroactively from January 1, 2012 to December 31, 2013. In the first quarter of 2013, we recognized the research and development tax credit related to 2012 as a favorable discrete item. Research and development tax credits generated in 2013 are being recognized pro-rata as a component of the overall 2013 effective tax rate.

(7) Earnings Per Share

A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows:

	Three Months Ended					
	2013			2012		
	Earnings	Shares	Per-Share	Earnings	Shares	Per-Share
(In thousands, except per share data)	(Numerato	r)Denominato	r)Amount	(Numerato	or@Denominato	r)Amount
Basic earnings per share:						
Income available to common shareholders	\$112,907	343,800	\$0.33	\$97,829	341,426	\$0.29
Effect of dilutive securities:						
Stock options and non-vested shares		8,685			9,842	
Diluted earnings per share:						
Income available to common shareholders	¢ 1 1 2 007	252 495	¢0.22	¢07.920	251 269	¢ 0 2 0
including assumed conversions	\$112,907	352,485	\$0.32	\$97,829	351,268	\$0.28

For the three months ended June 29, 2013 and June 30, 2012, options to purchase 6.3 million and 4.8 million shares of common stock at per share prices ranging from \$35.91 to \$49.43 and \$27.62 to \$42.98, respectively, were outstanding but were not included in the computation of diluted earnings per share because they were anti-dilutive.

	Six Months Ended					
	2013			2012		
	Earnings	Shares	Per-Share	Earnings	Shares	Per-Share
(In thousands, except per share data)	(Numerato	or(Denominato	or)Amount	(Numerato	r)Denominator	r)Amount
Basic earnings per share:						
Income available to common shareholders	\$222,947	343,976	\$0.65	\$186,537	340,671	\$0.55
Effect of dilutive securities:						
Stock options and non-vested shares		8,738			9,995	
Diluted earnings per share:						
Income available to common shareholders	\$222,947	352,714	\$0.63	\$186,537	350,666	\$0.53
including assumed conversions	\$ <i>222</i> ,947	332,714	Ф 0.05	φ100,337	330,000	ф0.33

For the six months ended June 29, 2013 and June 30, 2012, options to purchase 5.1 million and 4.0 million shares of common stock at per share prices ranging from \$32.92 to \$49.43 and \$25.80 to \$42.98, respectively, were outstanding but were not included in the computation of diluted earnings per share because they were anti-dilutive.

(8) Share-Based Compensation and Equity

Stock Options

Options activity for the six months ended June 29, 2013 was as follows:

Options activity for the six months ended June 29, 2013 wa	Options activity for the six months ended June 29, 2013 was as follows:						
		Weighted-	A gana gata	Weighted-Average			
(In the user de avaant nor share data)	Number of	Average	Aggregate Intrinsic	Remaining			
(In thousands, except per share data)	Shares	Exercise		Contractual			
		Price	Value	Term (Yrs)			
Outstanding at beginning of year	24,072	\$16.99					
Granted	3,575	47.66					
Exercised	(1,825)	9.42					
Forfeited and expired	(82)	34.55					
Outstanding as of June 29, 2013	25,740	21.73	\$678,232	6.59			
Exercisable as of June 29, 2013	14,886	\$10.45	\$559,575	5.11			

The weighted-average assumptions used to estimate the fair value of stock options granted in 2013 were as follows: Expected volatility (%) 30.4 % Expected term (yrs) 9.1 Risk-free rate (%) 1.9 % Fair value per option \$19.45 As of June 29, 2013, there was \$140.3 million of total unrecognized compensation cost related to stock options granted under all plans. That cost is expected to be recognized over a weighted-average period of 3.61 years. Non-vested Shares

Non-vested share activity for the six months ended June 29, 2013 was as follows:

(In thousands, except per share data)	Weighted-Ave Number of SharesGrant Date Fa Value			
Outstanding at beginning of year Granted Vested Forfeited	602 188 (272 (10))	\$ 28.41 46.65 23.81 22.73	
Outstanding as of June 29, 2013 As of June 29, 2013, there was \$13.3 million of total unrecognized compensation	508 cost relate	ed to no	\$ 37.73 n-vested share	

awards granted under all plans. That cost is expected to be recognized over a weighted-average period of 1.86 years.

The following table presents total compensation expense recognized with respect to stock options, non-vested shares and our associate stock purchase plan:

	Three Mor	nths Ended	Six Months Ended		
(In thousands)	2013	2012	2013	2012	
Stock option and non-vested share compensation expense	\$10,529	\$8,252	\$21,123	\$16,583	
Associate stock purchase plan expense	868	613	1,699	1,345	
Amounts capitalized in software development costs, net of amortization	(464)	(268)	(663)	(382)	
Amounts charged against earnings, before income tax benefit	\$10,933	\$8,597	\$22,159	\$17,546	
Amount of related income tax benefit recognized in earnings	\$4,242	\$3,288	\$8,598	\$6,711	

Treasury Stock

In December 2012, our Board of Directors authorized a stock repurchase program of up to \$170.0 million of our common stock. The repurchases are to be effectuated in the open market, by block purchase, or possibly through other transactions managed by broker-dealers. No time limit was set for completion of the program.

During the six months ended June 29, 2013, we repurchased 1.5 million shares (pre-split) for total consideration of \$141.8 million. These shares were recorded as treasury stock and accounted for under the cost method. All of the repurchased shares were utilized to settle a portion of the stock split distribution, as further described in Note 1 of these notes to condensed consolidated financial statements.

Authorized Shares

Effective May 24, 2013, we amended our Second Restated Certificate of Incorporation of Cerner Corporation to increase the number of authorized shares of our common stock from 250,000,000 to 500,000,000 shares.

(9) Hedging Activities

The following table represents the fair value of our net investment hedge included within the condensed consolidated balance sheets:

(In thousands)		Fair Value		
Derivatives Designated	Balance Sheet Classification	June 29, 2013	December 29, 2012	
Net investment hedge Net investment hedge		\$14,125 28,251	\$15,015 30,030	
Total net investment hedge		\$42,376	\$45,045	

The following table represents the related unrealized gain or loss, net of related income tax effects, on the net
investment hedge recognized in comprehensive income:
(In thousands)Net Unrealized GainNet Unrealized Gain

(Loss)

(Loss)

		For the Three Months Ended		For the Six Month Ended			
Derivatives Designated	Balance Sheet Classification	2013		2012	2013	2012	
, e	e Short-term liabilities e Long-term liabilities	\$(7 (3))	\$176 528	\$525 1,060	\$(100 (299))
Total net investment hedge		\$(10)	\$704	\$1,585	\$(399)

(10) Contingencies

The terms of our software license agreements with our clients generally provide for a limited indemnification of such clients against losses, expenses and liabilities arising from third party claims based on alleged infringement by our solutions of an intellectual property right of such third party. The terms of such indemnification often limit the scope of and remedies for such indemnification obligations and generally include a right to replace or modify an infringing solution. To date, we have not had to reimburse any of our clients for any losses related to these indemnification provisions pertaining to third party intellectual property infringement claims. For several reasons, including the lack of prior indemnification claims and the lack of a monetary liability limit for certain infringement cases under the terms of the corresponding agreements with our clients, we cannot determine the maximum amount of potential future payments, if any, related to such indemnification provisions.

(11) Segment Reporting

We have two operating segments, Domestic and Global. Revenues are derived primarily from the sale of clinical, financial and administrative information systems and solutions. The cost of revenues includes the cost of third party consulting services, computer hardware, devices and sublicensed software purchased from manufacturers for delivery to clients. It also includes the cost of hardware maintenance and sublicensed software support subcontracted to the manufacturers. Operating expenses incurred by the geographic business segments consist of sales and client service expenses including salaries of sales and client service personnel, communications expenses and unreimbursed travel expenses. "Other" includes expenses that have not been allocated to the operating segments, such as software development, marketing, general and administrative, share-based compensation expense and depreciation. Performance of the segments is assessed at the operating earnings level and, therefore, the segment operations have been presented as such. Items such as interest, income taxes, capital expenditures and total assets are managed at the consolidated level and thus are not included in our operating segment disclosures. Accounting policies for each of the reportable segments are the same as those used on a consolidated basis.

ended June 29, 2013 and June 30, 2012: (In thousands)	Domestic	Global	Other	Total
Three Months Ended 2013 Revenues	\$618,991	\$88,570	\$—	\$707,561
Cost of revenues Operating expenses Total costs and expenses	113,099 143,111 256,210	12,701 24,977 37,678	 247,217 247,217	125,800 415,305 541,105
Operating earnings (loss) (In thousands)	\$362,781 Domestic	\$50,892 Global	\$(247,217) Other	\$166,456 Total
Three Months Ended 2012 Revenues	\$561,658	\$75,700	\$—	\$637,358
Cost of revenues Operating expenses Total costs and expenses	137,652 120,443 258,095	9,848 32,071 41,919	 201,261 201,261	147,500 353,775 501,275
Operating earnings (loss)	\$303,563	\$33,781	\$(201,261)	\$136,083

The following table presents a summary of our operating segments and other expense for the three and six months ended June 29, 2013 and June 30, 2012:

(In thousands)	Domestic	Global	Other	Total
Six Months Ended 2013 Revenues	\$1,195,630	\$191,960	\$—	\$1,387,590
Cost of revenues Operating expenses Total costs and expenses	219,796 290,867 510,663	33,233 50,607 83,840	 470,062 470,062	253,029 811,536 1,064,565
Operating earnings (loss)	\$684,967	\$108,120	\$(470,062)	\$323,025
14				

Table of Contents

(In thousands)	Domestic	Global	Other	Total
Six Months Ended 2012 Revenues	\$1,115,932	\$162,638	\$—	\$1,278,570
Cost of revenues Operating expenses Total costs and expenses Operating earnings (loss)	271,955 240,881 512,836 \$603,096	33,553 64,822 98,375 \$64,263	 403,837 403,837 \$(403,837)	305,508 709,540 1,015,048 \$263,522

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following Management Discussion and Analysis (MD&A) is intended to help the reader understand the results of operations and financial condition of Cerner Corporation (Cerner, the Company, we, us or our). This MD&A is provided as a supplement to, and should be read in conjunction with, our financial statements and the accompanying notes to the financial statements (Notes) found above.

Our second fiscal quarter ends on the Saturday closest to June 30. The 2013 and 2012 second quarters ended on June 29, 2013 and June 30, 2012, respectively. All references to years in this MD&A represent the respective three or six months ended on such dates, unless otherwise noted.

On May 24, 2013, the Board of Directors of the Company approved a two-for-one split of our common stock in the form of a one hundred percent (100%) stock dividend, which was distributed on or about June 28, 2013 to shareholders of record as of June 17, 2013. In connection with the stock split, 1.5 million treasury shares, which represents the amount held in treasury on June 28, 2013, were utilized to settle a portion of the distribution. All share and per share data have been retroactively adjusted for all periods presented to reflect the stock split including the use of treasury shares, as if the stock split had occurred at the beginning of the earliest period presented.

Except for the historical information and discussions contained herein, statements contained in this quarterly report on Form 10-Q may constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended (the Exchange Act). Forward-looking statements can often be identified by the use of forward-looking terminology, such as "could," "should," "will," "intended," "continue," "believe," "may," "expect," "hope," "anticipate," "goal," "forecast," "plan," "guidance" or "estimate" or the negative of these words, variations thereof or similar expressions. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, including without limitation: the possibility of product-related liabilities; potential claims for system errors and warranties; the possibility of interruption at our data centers or client support facilities; our proprietary technology may be subject to claims for infringement or misappropriation of intellectual property rights of others, or may be infringed or misappropriated by others; risks associated with our non-U.S. operations; risks associated with our ability to effectively hedge exposure to fluctuations in foreign currency exchange rates; the potential for tax legislation initiatives that could adversely affect our tax position and/or challenges to our tax positions in the United States and non-U.S. countries; risks associated with our recruitment and retention of key personnel; risks related to our reliance on third party suppliers; risks inherent with business acquisitions; the potential for losses resulting from asset impairment charges; risks associated with the uncertainty in global economic conditions; managing growth in the new markets in which we offer solutions, health care devices and services; changing political, economic, regulatory and judicial influences; government regulation; significant competition and market changes; variations in our quarterly operating results; potential inconsistencies in our sales forecasts compared to actual sales; volatility in the trading price of our common stock and the timing and volume of market activity; the authority of our Board of Directors to issue preferred stock and anti-takeover provisions contained in our corporate governance documents; material adverse resolution of legal proceedings; and, other risks, uncertainties and factors discussed elsewhere in this Form 10-O, in our other filings with the Securities and Exchange Commission or in materials incorporated herein or therein by reference. Forward looking statements are not guarantees of future performance or results. The reader should not place undue reliance on forward-looking statements since the statements speak only as to the date they are made. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial condition or business over time.

Management Overview

Our revenues are primarily derived by selling, implementing and supporting software solutions, clinical content, hardware, devices and services that give health care providers secure access to clinical, administrative and financial

data in real time, allowing them to improve quality, safety and efficiency in the delivery of health care.

Our fundamental strategy centers on creating organic growth by investing in research and development (R&D) to create solutions and services for the health care industry. This strategy has driven strong growth over the long-term, as reflected in five- and ten-year compound annual revenue growth rates of 12% or more. This growth has also created an important strategic footprint in health care, with Cerner[®] solutions licensed by approximately 10,000 facilities around the world, including more than 2,700 hospitals; 4,150 physician practices; 45,000 physicians; 550 ambulatory facilities, such as laboratories, ambulatory centers, behavioral health centers, cardiac facilities, radiology clinics and surgery centers; 800 home health facilities; 45 employer sites and 1,750 retail pharmacies. Selling additional solutions back into this client base is an important element of our future revenue growth. We are also focused on driving growth through market share expansion by strategically

aligning with health care providers that have not yet selected a supplier and by displacing competitors in health care settings that are looking to replace their current supplier.

We expect to drive growth through new initiatives and services that reflect our ongoing ability to innovate and expand our reach into health care. Examples of these include our CareAware[®] health care device architecture and devices, employer services, Cerner ITWorksSM services, revenue cycle solutions, such as Cerner RevWorksSM services, and population health solutions and services. Finally, we believe there is significant opportunity for growth outside of the United States, with many non-U.S. markets focused on health care information technology as part of their strategy to improve the quality and lower the cost of health care.

Beyond our strategy for driving revenue growth, we are also focused on earnings growth. Similar to our history of growing revenue, our net earnings have increased at compound annual rates of more than 20% over the most recent five- and ten-year periods. We expect to drive continued earnings growth through ongoing revenue growth coupled with margin expansion, which we expect to achieve through efficiencies in our implementation and operational processes and by leveraging R&D investments and controlling general and administrative expenses.

We are also focused on continuing to deliver strong levels of cash flow, which we expect to accomplish by continuing to grow earnings and prudently managing capital expenditures.

Results Overview

The Company delivered strong levels of bookings, revenues, earnings and operating cash flows in the second quarter of 2013.

New business bookings revenue, which reflects the value of executed contracts for software, hardware, professional services and managed services, was \$935.0 million in the second quarter of 2013, which is an increase of 33% compared to \$700.5 million in the second quarter of 2012. Revenues for the second quarter of 2013 increased 11% to \$707.6 million compared to \$637.4 million in the second quarter of 2012. The year-over-year increase in revenue reflects improved economic conditions, ongoing demand related to the HITECH Act, and increased contributions from new initiatives, such as Cerner ITWorks and Cerner RevWorks.

Second quarter 2013 net earnings increased 15% to \$112.9 million compared to \$97.8 million in the second quarter of 2012. Diluted earnings per share increased 14% to \$0.32 compared to \$0.28 in the second quarter of 2012. The growth in net earnings and diluted earnings per share was driven by strong growth in services and higher margin components of system sales that more than offset a decline in technology resale. Additionally, our margin expansion initiatives, which include creating efficiencies in our implementation and operational processes, have contributed to our earnings growth.

Second quarter 2013 and 2012 net earnings and diluted earnings per share reflect the impact of stock-based compensation expense. The effect of these expenses reduced the second quarter 2013 net earnings and diluted earnings per share by \$6.7 million and \$0.02, respectively, and the second quarter 2012 net earnings and diluted earnings per share by \$5.3 million and \$0.01, respectively.

Our second quarter 2013 operating margin of 24% reflects an increase of 220 basis points compared to 2012, which was driven by the previously discussed margin expansion efforts and a lower mix of low-margin technology resale revenue.

We had cash collections of receivables of \$718.7 million in the second quarter of 2013 compared to \$679.6 million in the second quarter of 2012. Days sales outstanding was 68 days for the second quarter of 2013 compared to 69 days for the first quarter of 2013 and 71 days for the second quarter of 2012. Operating cash flows for the second quarter of

2013 were \$176.5 million compared to \$182.8 million in the second quarter of 2012.

Results of Operations

Three Months Ended June 29, 2013 Compared to Three Months Ended June 30, 2012

The following table presents a summary of the operating information for the second quarters of 2013 and 2012:

(In thousands)	2013	% of Reven	ue	2012	% of Revent	ıe	% Chang	ge
Revenues	¢ 200 502	20	01	¢ 105 2 05	0.1	đ	2	Ø
System sales	\$200,503		%	\$195,295	31	%		%
Support and maintenance	164,559	23	%	150,497	24	%		%
Services	322,088	46	%	275,549	43		17	%
Reimbursed travel	20,411	3	%	16,017	3	%	27	%
Total revenues	707,561	100	%	637,358	100	%	11	%
Costs of revenue								
Costs of revenue	125,800	18	%	147,500	23	%	(15)%
Total margin	581,761	82	%	489,858	77	%	19	%
Operating expenses								
Sales and client service	281,192	40	%	241,875	38		16	%
Software development	82,282	12	%	73,507	12		12	%
General and administrative	51,831	7	%	38,393	6	%	35	%
	415 205	50	01	252 775	50	Ø	17	Ø
Total operating expenses	415,305	59	%	353,775	56	%	17	%
Total costs and expenses	541,105	76	%	501,275	79	%	8	%
Total costs and expenses	541,105	70	70	501,275	12	70	0	\mathcal{H}
Operating earnings	166,456	24	%	136,083	21	%	22	%
Other income, net	2,733			2,814				
Income taxes	(56,282)		(41,068)				
Net earnings	\$112,907			\$97,829			15	%
Deveryon & Declale a								

Revenues & Backlog

•

Revenues increased 11% to \$707.6 million in the second quarter of 2013, as compared to \$637.4 million in the second quarter of 2012.

System sales, which include revenues from the sale of licensed software, software as a service, technology resale (hardware, devices, and sublicensed software), deployment period licensed software upgrade rights, installation fees, transaction processing and subscriptions, increased 3% to \$200.5 million in the second quarter of 2013 from \$195.3 million for the same period in 2012. The increase in system sales was driven by strong growth in licensed software, subscriptions and software as a service, partially offset by lower levels of technology resale.

Support and maintenance revenues increased 9% to \$164.6 million in the second quarter of 2013 compared to \$150.5 million during the same period in 2012. This increase was attributable to continued success at selling Cerner Millennium® applications and implementing them at client sites. We expect that support and maintenance revenues will continue to grow as the base of installed Cerner Millennium systems grows.

Services revenue, which includes professional services, excluding installation, and managed services, increased 17% to \$322.1 million in the second quarter of 2013 from \$275.5 million for the same period in 2012. This increase was

driven by growth in CernerWorksSM managed services as a result of continued demand for our hosting services and an increase in professional services due to increased implementation and consulting activities and growth in Cerner ITWorks and Cerner RevWorks services.

Contract backlog, which reflects new business bookings that have not yet been recognized as revenue, increased 25% in the second quarter of 2013 when compared to the same period in 2012. This increase was driven by growth in new business bookings during the past four quarters, including continued strong levels of managed services and Cerner ITWorks and Cerner RevWorks services bookings that typically have longer contract terms. A summary of our total backlog follows:

(In thousands)	June 29,June20132012	· ·
Contract backlog Support and maintenance backlog	\$7,244,030 \$5,79 756,858 713,9	,
Total backlog	\$8,000,888 \$6,5	13,388

Costs of Revenue

Cost of revenues as a percentage of total revenues was 18% in the second quarter of 2013, compared to 23% in the same period of 2012. The lower cost of revenues as a percent of revenue was driven by a lower mix of technology resale, which carries a higher cost of revenue.

Cost of revenues includes the cost of reimbursed travel expense, sales commissions, third party consulting services and subscription content and computer hardware, devices and sublicensed software purchased from manufacturers for delivery to clients. It also includes the cost of hardware maintenance and sublicensed software support subcontracted to the manufacturers. Such costs, as a percent of revenues, typically have varied as the mix of revenue (software, hardware, devices, maintenance, support, services and reimbursed travel) carrying different margin rates changes from period to period. Cost of revenues does not include the costs of our client service personnel who are responsible for delivering our service offerings. Such costs are included in sales and client service expense. Operating Expenses

Total operating expenses increased 17% to \$415.3 million in the second quarter of 2013, compared with \$353.8 million in the second quarter of 2012.

Sales and client service expenses as a percent of total revenues were 40% in the second quarter of 2013, compared to 38% in the same period of 2012. These expenses increased 16% to \$281.2 million in the second quarter of 2013, from \$241.9 million in the same period of 2012. Sales and client service expenses include salaries of sales and client service personnel, depreciation and other expenses associated with our CernerWorks managed service business, communications expenses, unreimbursed travel expenses, expense for share-based payments, sales and marketing salaries and trade show and advertising costs. The increase as a percent of revenue reflects a higher mix of services during the quarter.

Software development expenses as a percent of revenue were 12% in the second quarters of 2013 and 2012. Expenditures for software development reflect ongoing development and enhancement of the Cerner Millennium platform, with a focus on supporting key initiatives to enhance physician experience, revenue cycle and population health solutions. A summary of our total software development expense in the second quarters of 2013 and 2012 is as follows:

	Three Months Ended
(In thousands)	2013 2012
Software development costs	\$102,561 \$77,190
Capitalized software costs	(42,793) (23,183)
Capitalized costs related to share-based payments	(780) (584)
Amortization of capitalized software costs	23,294 20,084
Total software development expense	\$82,282 \$73,507

General and administrative expenses as a percent of total revenues were 7% in the second quarter of 2013, compared to 6% in the same period of 2012. These expenses increased 35% to \$51.8 million in 2013, from \$38.4 million for the same period in 2012. General and administrative expenses include salaries for corporate, financial and administrative staffs, utilities, communications expenses, professional fees, depreciation and amortization, transaction gains or losses on foreign currency and expense for share-based payments. The increase in general

and administrative expenses was primarily driven by an increase in corporate personnel costs, as we have continued to increase such personnel to support our overall revenue growth, and an increase in amortization expense due to acquired intangibles.

Non-Operating Items

Interest income decreased to \$3.8 million in the second quarter of 2013 from \$4.2 million in the same period of 2012, due to a slight decrease in the return on our investments. Interest expense decreased to \$1.0 million in the second quarter of 2013 compared to \$1.4 million in the same period of 2012 due to payments on our long-term debt and capitalized interest related to the construction of our new campus, partially offset by increased capital lease obligations.

Our effective tax rate was 33.3% for the second quarter of 2013 and 29.6% for the second quarter of 2012. This increase was primarily due to a decrease in net favorable discrete items recorded in 2013 relative to 2012, partially offset by reinstatement of the research and development credit in 2013. Refer to Note (6) of the notes to condensed consolidated financial statements.

Operations by Segment

We have two operating segments: Domestic and Global. The Domestic segment includes revenue contributions and expenditures associated with business activity in the United States. The Global segment includes revenue contributions and expenditures linked to business activity in Aruba, Australia, Australia, Canada, Cayman Islands, Chile, Egypt, England, France, Germany, Guam, India, Ireland, Israel, Malaysia, Mexico, Qatar, Saudi Arabia, Singapore, Spain, Switzerland and the United Arab Emirates.

The following table presents a summary of the operating information for the second quarters of 2013 and 2012:

(In thousands)	2013	% of Revenue	2012	% of Revenue	% Change
Domestic Segment					
Revenues	\$618,991	100%	\$561,658	100%	10%
Costs of revenue	113,099	18%	137,652	25%	(18)%
Operating expenses	143,111	23%	120,443	21%	19%
Total costs and expenses	256,210	41%	258,095	46%	(1)%
Domestic operating earnings	362,781	59%	303,563	54%	20%
Global Segment					
Revenues	88,570	100%	75,700	100%	17%
Costs of revenue	12,701	14%	9,848	13%	29%
Operating expenses	24,977	28%	32,071	42%	(22)%
Total costs and expenses	37,678	43%	41,919	55%	(10)%
Global operating earnings	50,892	57%	33,781	45%	51%
Other, net	(247,217))	(201,261)		23%
Consolidated operating earnings	\$166,456		\$136,083		22%

Domestic Segment

Revenues increased 10% to \$619.0 million in the second quarter of 2013 from \$561.7 million in the same period of 2012. This increase was driven by strong growth across most of our business, offset by lower levels of technology resale.

Cost of revenues was 18% of revenues in the second quarter of 2013, compared to 25% of revenues in the same period of 2012. The lower cost of revenues as a percent of revenue was primarily driven by a lower mix of technology resale, which carries a higher cost of revenue.

Operating expenses increased 19% to \$143.1 million in the second quarter of 2013 from \$120.4 million in the same period of 2012, due primarily to growth in professional services expenses.

Global Segment

Revenues increased 17% to \$88.6 million in the second quarter of 2013 from \$75.7 million in the same period of 2012. This increase was primarily driven by strong growth in professional services.

Cost of revenues was 14% in the second quarter of 2013 and 13% in the same period of 2012. The higher cost of revenues in 2013 was primarily driven by an increase in third party professional services costs.

Operating expenses were at \$25.0 million in the second quarter of 2013, compared to \$32.1 million in the same period of 2012, primarily due to a decrease in bad debt expense.

Other, net

Operating results not attributed to an operating segment include expenses, such as centralized professional services costs, software development, marketing, general and administrative, stock-based compensation, depreciation, and amortization. These expenses increased 23% to \$247.2 million in the second quarter of 2013 from \$201.3 million in the same period of 2012. This increase was primarily due to growth in corporate and development personnel costs, along with increased depreciation and amortization related to acquired assets. This was partially offset by increased software capitalization.

Six Months Ended June 29, 2013 Compared to Six Months Ended June 30, 2012

The following table presents a summary of the operating information for the first six months of 2013 and 2012:

(In thousands)	2013	% of Revenue		2012	% of Revenue		% Change	
Revenues System sales Support and maintenance	\$399,405 325,516	29 23	% %	\$421,115 296,251	33 23	% %	(5 10)% %
Services	627,687	45	%	533,699	42	%		%
Reimbursed travel	34,982	3	%	27,505	2	%	27	%
Total revenues	1,387,590	0 100	%	1,278,570	100	%	9	%
Costs of revenue Costs of revenue	253,029	18	%	305,508	24	%	(17)%
	200,027	10	70	200,200	2.	70	(17)//0
Total margin	1,134,561	82	%	973,062	76	%	17	%
Operating expenses								
Sales and client service	548,548	40	%	486,949	38	%	13	%
Software development	163,345	12	%	144,652	11	%	13	%
General and administrative	99,643	7	%	77,939	6	%	28	%
Total operating expenses	811,536	58	%	709,540	55	%	14	%
Total costs and expenses	1,064,565	5 77	%	1,015,048	79	%	5	%
Operating earnings	323,025	23	%	263,522	21	%	23	%
Other income, net Income taxes	5,777 (105,855)		5,438 (82,423)				

Edgar Filing: CERNER CORP /MO/ - Form 10-Q						
Net earnings	\$222,947	\$186,537	20	%		

Revenues & Backlog

Revenues increased 9% to \$1.4 billion in the first six months of 2013, as compared to \$1.3 billion in the first six months of 2012.

System sales decreased 5% to \$399.4 million in the first six months of 2013 from \$421.1 million for the same period in 2012. The decrease in system sales was driven by lower levels of technology resale, which more than offset growth in subscriptions, software as a service and licensed software.

Support and maintenance revenues increased 10% to \$325.5 million in the first six months of 2013 compared to \$296.3 million during the same period in 2012. This increase was attributable to continued success at selling Cerner Millennium applications and implementing them at client sites. We expect that support and maintenance revenues will continue to grow as the base of installed Cerner Millennium systems grows.

Services revenue increased 18% to \$627.7 million in the first six months of 2013 from \$533.7 million for the same period in 2012. This increase was driven by growth in CernerWorks managed services as a result of continued demand for our hosting services and an increase in professional services due to increased implementation and consulting activities.

Costs of Revenue

Cost of revenues as a percentage of total revenues was 18% in the first six months of 2013, compared to 24% in the same period of 2012. The lower cost of revenues as a percent of revenue was driven by a lower mix of technology resale, which carries a higher cost of revenue.

Operating Expenses

Total operating expenses increased 14% to \$811.5 million in the first six months of 2013, compared with \$709.5 million in the same period of 2012.

Sales and client service expenses as a percent of total revenues were 40% in the first six months of 2013, compared to 38% in the same period of 2012. These expenses increased 13% to \$548.5 million in the first six months of 2013, from \$486.9 million in the same period of 2012. The increase as a percent of revenue reflects a higher mix of services in 2013.

Software development expenses as a percent of revenue were 12% in the first six months of 2013, compared to 11% in the same period of 2012. Expenditures for software development reflect ongoing development and enhancement of the Cerner Millennium platform, with a focus on supporting key initiatives to enhance physician experience, revenue cycle and population health solutions. A summary of our total software development expense in the first six months of 2013 and 2012 is as follows:

	Six Months Endec				
(In thousands)	2013	2012			
Software development costs	\$195,942	\$152,026			
Capitalized software costs	(76,613)	(45,834)			
Capitalized costs related to share-based payments	(1,294)	(1,013)			
Amortization of capitalized software costs	45,310	39,473			
Total software development expense	\$163,345	\$144,652			

General and administrative expenses as a percent of total revenues were 7% in the first six months of 2013, compared to 6% in the same period of 2012. These expenses increased 28% to \$99.6 million in 2013, from \$77.9 million for the same period in 2012. The increase in general and administrative expenses was primarily driven by an increase in corporate personnel costs, as we have continued to increase such personnel to support our overall revenue growth, and an increase in amortization expense due to acquired intangibles.

Table of Contents

Non-Operating Items

Interest income decreased to \$7.9 million in the first six months of 2013 from \$8.3 million in the same period of 2012, due to a slight decrease in the return on our investments. Interest expense decreased to \$2.1 million in the first six months of 2013 compared to \$2.9 million in the same period of 2012 due to payments on our long-term debt and capitalized interest related to the construction of our new campus, partially offset by increased capital lease obligations.

Our effective tax rate was 32.2% for the first six months of 2013 and 30.6% for the first six months of 2012. This increase was primarily due to a decrease in net favorable discrete items recorded in 2013 relative to 2012, partially offset by reinstatement of the research and development credit in 2013. Refer to Note (6) of the notes to condensed consolidated financial statements.

Operations by Segment

The following table presents a summary of the operating information for the first six months of 2013 and 2012:

(In thousands)	2013	% of	2012	% of
	2013	Revenue	2012	Revenue